America - A Diversity of Lifestyles

BAY 43-9006, an oral inhibitor targeting multiple kinases, was studied in a Phase I trial, establishing a recommended Phase II dose of 400 mg twice daily. In a Phase II study involving 41 patients with renal cell carcinoma, 30% achieved stable disease, 40% responded with significant reduction, and 30% experienced disease progression. The drug's side effects, including hypertension, edema, diarrhea, hand and foot syndrome, rash, and hair loss, were manageable. A Phase III trial was initiated for patients with disease progression post-immunotherapy, and combination studies were being considered. The exact therapeutic targets in renal cell carcinoma were unclear, as BRAF mutations were not present, suggesting VEGFR2 and VEGFR3 as potential targets.